There is limited knowledge about longitudinal genotype-specific concordance between human papillomavirus (HPV) serology and co-existent presence of HPV DNA in the uterine cervix. The role of oral HPV infections in inducing serological response is unclear, as is the effect of HPV antibodies on the outcome of oral HPV infections. The present study is part of the Finnish Family HPV Study designed to evaluate dynamics of HPV infections within families. Here, we correlated the point prevalence of HPV6, 11, 16, 18 and 45 antibodies and concomitant genotype-specific HPV DNA detection in cervical and oral samples of 323 mothers during their 3 year (mean 37.5 months) follow-up. The mean age of these pregnant mothers at enrolment (third trimester) was 25.5 years. HPV antibodies were analysed with multiplex HPV serology and HPV genotyping was performed using a Multimetrix kit (Progen Biotechnik). There was no concordance between cervical DNA detection and co-existent seropositivity, and the same was true even in samples taken 12 months apart. Women who cleared their cervical HPV16 infection had the highest HPV16 antibody levels, whereas those who acquired incident HPV16 infections had the lowest antibody levels. Neither the presence nor the dynamics of oral HPV DNA had any correlation with HPV serology.
INTRODUCTION
Persistent human papillomavirus (HPV) infection is a major causal factor for cervical cancer (CC) and its precursors (cervical intraepithelial neoplasia, CIN), with the two most important oncogenic types being 16 and 18 (Li et al., 2011) . DNA tests are the methods of choice to detect HPV infections. The median duration of HPV infection for any types has been within the range of 4 to 20 months (Ho et al., 1998; Richardson et al., 2003; Schiffman & Kjaer, 2003; Trottier & Franco, 2006) . Thus, because the majority of HPV infections will spontaneously clear, HPV DNA detection is not particularly suitable to assess the cumulative lifetime exposure to the virus.
Serological response could be a more informative measure of past HPV exposure (Combita et al., 2002) . The problem is, however, that HPV infection does not invariably lead to measurable antibody response; only half of HPV DNApositive women are also HPV seropositive (Carter et al., 2000; Clifford et al., 2007; Ho et al., 2004) . In addition to the risk of CIN and CC, HPV seroresponse in women seems to be also linked with their sexual debut, lifetime number of sexual partners, marital status, history of genital warts and herpes simplex virus type 2 (HSV2) seropositivity (Castle et al., 2002; Dillner et al., 1996; Kreimer et al., 2004; Syrjänen et al., 2009) . Probably the failure to develop an appropriate antibody response to HPV is linked with subsequent recurrence or persistence of HPV infection (Frazer, 1996) . The effects of innate immunity and acquired immunity on HPV clearance are not fully defined yet.
In 1998, we designed a prospective cohort study, the Finnish Family HPV Study, to understand the HPV dynamics in parents and their newborn offspring (Rintala et al., 2006) . As part of that study, we recently reported seroprevalence, seroconversion and antibody decay in 290 mothers during a 3 year follow-up. We found that a substantial proportion of these women (mean age of 25.5 years at baseline) were seropositive for both low-risk (LR) and high-risk (HR) HPV types. At baseline, seroprevalence of HPV6, 11, 16, 18 and 45 was 53.3, 21.5, 34.9, 21 .5 and 9.0 %, respectively. Also seroconversions to LR and HR HPVs were frequent, occurred within 18-24 months and were predicted by several covariates in common. In contrast, HPV antibody decay was a rare and more delayed event (Syrjänen et al., 2009) . The present study is a direct continuation of this analysis, comparing type-specific HPV serology and the presence of the same HPV types in cervical and oral samples at different time points during the 3 year follow-up. The main focus of this analysis was first to assess the outcome of the genotypespecific concordance and second, the association between levels of antibodies with the outcome of the HPV infection in cervix and oral mucosa.
RESULTS
Because HPV serology was only available for HPV types 6, 11, 16, 18 and 45, only these genotypes were considered while assessing the serology-DNA concordance in cervical and oral samples.
Concordance of type-specific seroresponse and cervical HPV DNA detection Serological response to L1 proteins of HPV6, 11, 16, 18 and 45 was assessed at each follow-up(FU) visit as depicted in Table 1 . In the pair-wise comparison of the samples taken at the same visit, there was no concordance between the type-specific HPV DNA status and seroresponse to the corresponding HPV type. To account for the time lag in developing serological response following HPV infection, the same data were also analysed by comparing the samples taken 12 months apart (i.e. baseline HPV DNA compared with 12 month serology, 12 month DNA to 24 month serology, etc.) (Table 2) . Again, concordance between HPV serology and HPV DNA was lacking.
Type-specific outcomes of cervical HPV infections as related to longitudinal HPV antibody levels In this cohort, six different outcomes have been identified for cervical HPV infections: (i) always negative, (ii) incident HPV infection (women who were HPV-negative at baseline and acquired new HPV infection during the FU), (iii) type-specific persistence, (iv) non-type-specific persistence, (v) fluctuation (intermittently HPV+ and HPV2), and (vi) clearance (transient) (Louvanto et al., 2010a (Louvanto et al., , b, 2011 .
The mean HPV antibody titres at each FU visit of the mothers ascribed to any of these six different outcomes of their cervical HPV are compared in Table 3 . There were no differences (at any of the FU visits) in titres of HPV6, 11 and 45 antibodies between the six outcome patterns, in contrast to HPV16 antibody levels, which were significantly different between the six HPV outcomes at all time points (P50.006-P50.042). The same was true for HPV18 antibody titres measured at the 24 month FU visit. Of the six outcome patterns, the highest (mean) levels of HPV16 antibodies were recorded among women who cleared their HPV16 infection, whereas the lowest levels were detected among those who acquired incident HPV16 infections. In ANOVA post-hoc analysis (LSD), the differences in HPV16 titres between incident and cleared cases was significant at all visits: P50.024, P50.002, P50.007 and P50.005, for baseline, 12, 24 and 36 months, respectively. The levels of HPV11 antibodies were significantly lower than HPV6 antibodies at each visit (P50.0001 for all; one-sample t-test).
It was of interest to compare the dynamics of genotypespecific HPV serology in two pairs of mothers: (i) those with incident HPV versus those remaining HPV-negative throughout the FU, and (ii) mothers with genotype-specific persistence versus those who cleared their infection. In the first pair (incident HPV vs always HPV-negative), no differences in HPV antibody titres at any of the FU visits could be established between the two groups ( Table 4) . The same was true with the rates and times of type-specific seroconversion (positive or negative). In the second pair (persistent infections vs clearance), a significant difference was found in HPV18 titres, which were markedly higher among women who cleared their HPV18 infections than in those with persistent HPV18 (Table 5) . This difference was seen at baseline, 12 and 24 months FU visits, but disappeared at the 36 months FU visit. However, the rates of and times to seroconversion were not different for any of the five HPV genotypes included in the test panel.
Oral HPV infections
The same analyses reported in Tables 1-5 were repeated for oral HPV samples as well, but we failed to demonstrate any concordance or association between the type-specific antibody titres and the outcome patterns of oral HPV infections.
DISCUSSION
In the present study, three important results were obtained. (i) There was no type-specific concordance between cervical HPV DNA detection and HPV seropositivity.
(ii) The highest levels of HPV type-specific antibodies were detected in those women who cleared their HPV16 infection. Those who acquired incident HPV16 infections had the lowest HPV16 antibody levels. (iii) Neither the presence nor the dynamics of oral HPV DNA had any correlation with HPV serology.
The HPV serology assays currently used are heterogeneous, some measuring total antibodies, whereas others measure specific neutralizing antibodies (Frazer et al., 2011) . In large seroepidemiological studies, HPV antibody detection has been associated with increased risk of different cancers, 
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Journal of General Virology 92 including those in the genital tract or head and neck region (Mork et al., 2001; Clifford et al., 2007; Furniss et al., 2009; Vaccarella et al., 2010) . Until now, one of the major disappointments in HPV serology has been the missing (or at best low) temporal correlation between HPV antibody response and HPV DNA detection, i.e. concordance in the samples taken at the same time point. Only about half of all HPV16 DNA-positive women have tested positive for the corresponding HPV type with the current serological assays (Kirnbauer et al., 1994; Wideroff et al., 1996; Carter et al., 1996 Carter et al., , 2000 Viscidi et al., 1997; Ho et al., 2004; Skjeldestad et al., 2008) . Skjeldestad et al. (2008) reported that among women who were seropositive for HPV6, 11, 16 and 18, the proportion of type-specific DNA-positive women was 38.6, 17.4, 47.5 and 42.1 %, respectively. One reason for this discordance can be that HPV serology also detects the past exposures to HPV. However, there is evidence that transient HPV infections do not always elicit seroconversion and, importantly, some women with persistent infection fail to seroconvert as well (Carter et al., 2000) . Furthermore, most of the serological studies of women with genital HPV infections have been cross-sectional in design, which precludes the analysis of seroconversion following HPV DNA detection in the cervix.
The immune response to L1 gene has been studied with HPV type-specific virus-like particles (VLPs), because HPV cannot be cultivated in vitro (Chen et al., 2011) . A possible hypothesis is that the wild-type L1 gene could produce stronger antibody response than the mutant L1 gene will do. The mutant L1 gene will not attach to the antigen and therefore will reduce the antibody production. If a person has a mutant L1 gene presumably they will become reinfected more easily because of an insufficient immune response. One way to search if the L1 gene is a mutant is to sequence the gene, which is quite laborious. In our study, one contingent explanation for the missing serology response could indeed be a mutant L1 gene that could not generate an antibody response strong enough to be detected with the Luminex glutathione S-transferase assay.
In the present study, we could not confirm any concordance between cervical HPV16 DNA and HPV16 serology. We expected to find concordance particularly for HPV16 because it is the most common genotype and has the longest persistence (Ralston Howe et al., 2009; Louvanto et al., 2010a; Nielsen et al., 2010) . It is also the most oncogenic, and possibly a more immunogenic type than others. Some studies also suggest selective transmission of different HPV types, HPV16 being the most readily transmitted type (Richardson et al., 2003; Goodman et al., 2008) . As to the temporal relationship, we could not disclose any significant lag in detecting concordant antibodies following the detection of HPV16 DNA in the cervix. In his series, Carter et al. (2000) described four of five women to be HPV16 or HPV18 DNA positive at every visit after 1 year, but they never seroconverted. In contrast, de Gruijl et al. (1997) found persistent HPV16 DNA and detectable HPV16 serum antibodies in all 11 women in 
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Journal of General Virology 92 their cohort. There could be many reasons for divergent results: some tentative evidence exists implying that several inherent factors can affect an individual's capacity to produce an HPV antibody response. One such factor is cigarette smoking, which seems to markedly impair this serological reactivity (Giorgi et al., 2008) .
There are several feasible explanations for this discrepancy between HPV DNA detection and concomitant HPV antibodies. Most likely, women in different studies are at different stages (phases) of their HPV infection which certainly affects the seroprevalence. Our cohort is different from most other cohorts in that all women were pregnant at their baseline visit, scheduled during the third trimester (Rintala et al., 2005b) . The effect of pregnancy on HPV detection and particularly HPV serology has not been studied in detail. Our preliminary data from this cohort showed that women who had a second pregnancy during the follow-up had lower HPV prevalence than women with only this index pregnancy . Similar results have also been reported recently by Domža et al. (2010) , who also reported that IL-10 and IL-12 concentrations were related to cervical HPV. Thus, there is a chance that HPV infection during pregnancy might be undetectable by usual HPV testing, and after delivery, the virus can reactivate leading to serological response. Another possibility is that after pregnancy, an exposure to new HPV genotype takes place, resulting in the same. Recently, Trottier et al. (2010) showed that reinfection or new infection was often associated with new sexual partners. The same applies to the present cohort as well, where one of the predictors of detectable HPV16, 18 and 45 HPV antibodies was the lifetime number of sexual partners (Syrjänen et al., 2009) . This is in line with the earlier studies (Carter et al., 1996; Olsen et al., 1997; Viscidi et al., 1997; Castle et al., 2002; Stone et al., 2002; Clifford et al., 2007; Skjeldestad et al., 2008) . In the same study, we identified two additional independent predictors of HPV seropositivity: (i) being seropositive for LR-HPV, and (ii) history of genital warts (Syrjänen et al., 2009) .
The vaccination studies have revealed much higher antibody levels after vaccination than after natural HPV infections. High antibody levels have been related to the effect of vaccine to protect against HPV (Carter et al., 1996; Hagensee et al., 1999 Villa et al., 2006) . However, the antibody levels needed for sustained type-specific HPV protection after vaccination are unknown. Natural history studies have shown that incidence and/or prevalence of newly detected HPV infections decline with age in most populations (Bosch et al., 2008; Syrjänen et al., 2009) . Although part of this decline probably reflects reduced exposure to HPV, secondary to fewer sexual partners at older ages, the cumulative effect of naturally acquired immunity may also be contributory. It is therefore reasonable to hypothesize that antibodies that are elicited by natural infection might protect the host against HPV reinfection with the same or related HPV type or aid in quick clearance. It was recently shown that sustained detection of IgG antibodies to HPV16 VLPs was associated with approximately 50 % less risk of subsequent HPV16 infection (Ho et al., 2002; Safaeian et al., 2010) .
Unfortunately, there are almost no longitudinal data on HPV serology and outcome of HPV infections assayed by their DNA detection. Albeit preliminary, some emerging data were elaborated in the present study, implying that HPV serology might bear some relationship to the outcome of these infections. Indeed, for HPV16 (and to a lesser extent for the others) we could demonstrate that the antibody levels were the highest among women who eventually cleared their HPV16 DNA during the follow-up (Table 3) . This clearly substantiates the recent observations of Safaeian et al. (2010) , who suggested that the protection against HPV is conferred among those with the highest antibody levels. In contrast, the antibody levels of HPV16 (and HPV18) were generally the lowest among those women who acquired an incident HPV16 (HPV18) infection, possibly implicating an insufficient level of protection or no prior infection. It was noteworthy, at all visits, that the difference in HPV16 titres (but not those of HPV18) between incident and cleared cases was highly significant, emphasizing the potential contribution of serological response to these two extreme viral outcomes (incident vs clearance).
There are controversial views on the association of HPV with different oral disorders. The following HPV types are found even in normal mucosa, with their significance remaining unclear: HPV2, 6, 7, 11, 13, 16, 18, 31, 33 and 35 (Syrjänen et al., 2011) . At present, altogether 24 HPV types have been detected from the oral mucosa (in benign, precancer or malignant lesions), and 13 of those are HRHPVs and probable HR-HPVs that have been associated with oral cancer. Numerous studies have detected HPV from the clinically normal oral mucosa, but the results are discordant, at least in part because of different sampling techniques and sensitivity, and specificity of the HPV testing methods (Syrjänen et al., 2011) . Similar to other mucosal sites, also in oral mucosa, HPV16 is the most common oncogenic type, followed by HPV18.
Asymptomatic HPV infections in oral mucosa are not that uncommon (Kellokoski et al., 1992; Puranen et al., 1996; Pintos et al., 2008) , but none of the studies have analysed serological responses evoked by these oral HPV infections. This was done for the first time in the present study, with disappointing results. We failed to find any evidence that oral HPV infection in women would elicit a detectable HPV antibody response. This supports the concept that cervical mucosa is the most important site of HPV infection from the serological point of view. Seroprevalence to HPV6 and HPV11 was common in this cohort (Syrjänen et al., 2009), and we speculated that part of this HPV6-and HPV11-immunoreactivity could be caused by HPV exposure at nongenital sites. As far as pertinent is to oral mucosa, this is not supported by the present results. However, we do not know the HPV history of these women before the enrolment in our cohort. There still remains a possibility that oral HPV infections might play a role before the onset of sexual activity, but this can only be studied in infants followed-up for a long enough time period.
To conclude, although preliminary, our results are encouraging in that they provide some circumstantial evidence Concordance of HPV serology and DNA implying that a fraction of young women with higher natural HPV antibody levels might be protected against persistent or new HPV infection, while those with low antibody levels are more susceptible to incident HPV infections.
METHODS
Subjects. The Finnish Family HPV Study is a longitudinal cohort study conducted at Turku University Hospital and University of Turku, Finland. The flow chart of the study has previously been described in detail (Rintala et al., 2006) . In total, 329 families were enrolled, comprising 329 mothers enrolled at 36 weeks (min) of their index pregnancy, 131 fathers and 331 newborns (Rintala et al., 2006) . The Research Ethics Committee of Turku University Hospital approved the study protocol and its amendment ( # 2/1998 and # 2/2006).
The present analysis correlated the point prevalence of genotypespecific HPV antibodies and concomitant HPV DNA detection in cervical and oral mucosal samples of these 329 mothers during their 3 year (median 37.5 months; range 32.7-49.3 months) follow-up. Their mean age at the time of enrolment was 25.5 years (median 26.0 years). Of the 329 women originally enrolled, 323 women were eligible for the present study, all having at least two serum samples taken during the study period. The study design and methods of the Finnish Family HPV Study have been described in detail before (Rintala et al., 2005a (Rintala et al., , b, 2006 Louvanto et al., 2010b) , and are only briefly reiterated here as far as pertinent to the present study.
Samples. Cervical and oral scrapings for HPV testing were taken at baseline and at 2, 12, 24 and 36 months FU visits. Cervical scrapings were taken with a cytobrush (Cytobrush; MedScand) using 0.05 M PBS with 100 mg gentamicin as sampling medium. The samples were immediately frozen at 220 uC and stored at 270 uC. Scrapings from the oral cavity were taken from the buccal mucosa of both cheeks as well as from the upper and lower vestibular area using a small cytobrush (Cytobrush; MedScan). The brush was immersed in 80 % ethanol, frozen and stored at 270 uC (Rintala et al., 2006) .
HPV DNA testing. HPV DNA was extracted from the scrapings using the high salt-method (Miller et al., 1988) . HPV testing was performed by using nested PCR with MY09/MY11 as external primers and GP05+/GP06+ as internal primers (Snijders et al., 1990) . The PCR products were hybridized with a digoxigenin-labelled HR-HPVoligoprobe cocktail (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56 and 58) , following the method previously described by us (Anttila et al., 1999) .
HPV genotyping. HPV genotyping was performed using a Multimetrix kit (Progen Biotechnik), which detects the following 24 LR-and HR-HPV-genotypes: 11, 42, 43, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82. The test was performed as described in the protocol, except that we reamplified the above described nested PCR products for biotinylation with GP05+/bioGP06+-primers. The hybrids were analysed using a Luminex analyser (Bio-Plex 200 System; Bio-Rad Laboratories). The median fluorescence intensity (MFI) of at least 100 beads was computated for each bead set in the sample. The cut-off value for each run and HPV-type was calculated as 1.5 times background MFI (negative control)+5 MFI. All HPV16-positive samples were retested using the original sample, nested PCR and bead-based HPV-genotyping (Schmitt et al., 2006) to exclude potential contamination. Here, only the presence of HPV types 6, 11, 16, 18 and 45 in cervical or oral samples was used for the concordance analysis.
Serology. Blood samples were taken at baseline and at 12, 24 and 36 months of FU. After collection, blood samples were centrifuged at 2400 r.p.m. for 10 min (Sorvall GLC-2; DuPont Instruments); serum was divided into three 1 ml aliquots and stored first at 220 uC for no longer than 1 week and then at 270 uC until sent for analysis at the DKFZ, Heidelberg, Germany. Antibodies to the major capsid protein L1 of HPV types 6, 11, 16, 18 and 45 were analysed by multiplex HPV serology based on glutathione S-transferase fusionprotein capture on fluorescent beads, as described previously (Waterboer et al., 2005 . Sera were scored as positive when the antigen-specific MFI values were greater than the cut-off level of 200 or 400 MFI (stringent) for L1 antigen of individual HPV types (Michael et al., 2008) . Seroconversion was defined by two conditions: (i) an MFI value below 200 in the first and above 200 in the second sample, and (ii) at least a twofold increase of the previous serum value. Similarly, antibody decay was defined by two conditions: (i) an MFI value above 200 in the first and below 200 in the second sample, and (ii) at least a twofold decrease of the previous serum value. The genotype-specific concordance was calculated between HPV antibodies and HPV DNA detection (in cervical and oral samples) at each time point during the FU period. We used regular (nonweighted) Cohen's kappa, with 95 % confidence intervals (CI) calculated using the exact method. Kappa values were interpreted as follows: 0.00-0.20, poor agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; 0.81-1.00, almost perfect agreement. All tests were two-sided, and the results with P,0.05 were interpreted as statistically significant.
